Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Clinical trial NCT06967610 · RECRUITING
Trial details
- NCT number
- NCT06967610
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-15
- Primary completion
- 2031-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.